Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

VivoSpheres: Tissue-Engineered Spheroidal Models for High-Throughput Screening

Award Number: R43TR004754
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/22/2024
PERIOD OF PERFORMANCE END DATE: 05/23/2026

Group Awards By:

View Award Description

VivoSpheres: Tissue-Engineered Spheroidal Models for High-Throughput Screening - ABSTRACT The development of three-dimensional (3D) disease models has paved the way for accelerated design, discovery, and validation of potential targets and drug compounds, thereby significantly reducing the time, cost, and labor involved in the drug discovery pipeline. 3D spheroidal cell aggregate models have been established as more accurate and predictive than two-dimensional (2D) models for drug screening. However, current commercial techniques for spheroidal tissue formation rely heavily on the self-aggregation of single cells and have substantial limitations concerning production consistency, control, and flexibility. That makes VivoSphere a breakthrough product. VivoSpheres are cell-laden hydrogel microspheres that are produced rapidly using our microfluidic platform. Compared to self-aggregation systems, incorporation of hydrogel matrices in VivoSpheres can improve the consistency of tissues in size and shape, which is critical in getting high-quality results in high-throughput screening (HTS), and provide the ability to manipulate the cellular microenvironment, which is an important driver of appropriate cell phenotype and function. The cell types will no longer be limited to self-aggregating cells. Instead, there will be great flexibility in selecting either aggregating or non-aggregating cells, and even multiple cell types for co-encapsulation. This project will use cancer cells to demonstrate the high consistency of VivoSpheres as more suitable for HTS compared to self-aggregation systems, establish the ability to form VivoSpheres using non-aggregating cancer cells, and optimize key assays used in HTS. The outcome of this project will remove potential roadblocks to building disease-specific models for HTS. VivoSphere is VivoSphere LLC’s first product and is protected by non-provisional patents.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $350,000 )
2024	2024	VIVOSPHERE LLC	540 DEVALL DR STE 101	AUBURN	AL	36832	LEE	USA	National Center for Advancing Translational Sciences	000	1	5/22/2024	NEW	$350,000
														Subtotal = $350,000

Grand Total All Awards = $350,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

VivoSpheres: Tissue-Engineered Spheroidal Models for High-Throughput Screening

Award Number: R43TR004754

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/22/2024

PERIOD OF PERFORMANCE END DATE: 05/23/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer